Journals – 2013

 

1.
Galdiero S, Falanga A, Cantisani M, Vitiello M, Morelli G, Galdiero M. Peptide-lipid interactions: experiments and applications. Int J Mol Sci. 2013;14(9):18758-18789. [PubMed]
2.
Gaikwad S, Ingle A, Gade A, et al. Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3. Int J Nanomedicine. 2013;8:4303-4314. [PubMed]
3.
Cantisani M, Leone M, Mignogna E, et al. Structure-activity relations of myxinidin, an antibacterial peptide derived from the epidermal mucus of hagfish. Antimicrob Agents Chemother. 2013;57(11):5665-5673. [PubMed]
4.
Smaldone G, Falanga A, Capasso D, et al. gH625 is a viral derived peptide for effective delivery of intrinsically disordered proteins. Int J Nanomedicine. 2013;8:2555-2565. [PubMed]
5.
Tarallo R, Carberry T, Falanga A, et al. Dendrimers functionalized with membrane-interacting peptides for viral inhibition. Int J Nanomedicine. 2013;8:521-534. [PubMed]
6.
Galdiero S, Falanga A, Tarallo R, et al. Peptide inhibitors against herpes simplex virus infections. J Pept Sci. 2013;19(3):148-158. [PubMed]
7.
Scudiero O, Galdiero S, Nigro E, et al. Chimeric beta-defensin analogs, including the novel 3NI analog, display salt-resistant antimicrobial activity and lack toxicity in human epithelial cell lines. Antimicrob Agents Chemother. 2013;57(4):1701-1708. [PubMed]
8.
de A, Liguori L, Falanga A, et al. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(4):287-302. [PubMed]
9.
Guarnieri D, Falanga A, Muscetti O, et al. Shuttle-mediated nanoparticle delivery to the blood-brain barrier. Small. 2013;9(6):853-862. [PubMed]
10.
Cantisani M, Falanga A, Incoronato N, et al. Conformational modifications of gB from herpes simplex virus type 1 analyzed by synthetic peptides. J Med Chem. 2013;56(21):8366-8376. [PubMed]